

## Symposium

# RNAi – Reaching for therapy

• RNAi delivery • miRNAs • in vivo applications

25 October 2006

Institut Pasteur, Paris

9.30 - 17.30

## Speakers

**Patrick Arbuthnot** (University of the Witwatersrand, South Africa)

**Irene Bozzoni** (Università degli Studi di Roma "La Sapienza", Italy)

**Annick Harel-Bellan** (IAL CNRS, Villejuif, France)

**Stephan Kissler** (MIT, Cambridge, USA)

**Jørgen Kjems** (University of Aarhus, Denmark)

**Ralf Kühn** (GSF, Neuherberg, Germany)

**Luigi Naldini** (Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy)

**Cédric Raoul** (Swiss Federal Institute of Technology EPFL, Lausanne, Switzerland)

**Christina Rondinone** (Hoffman-La Roche, Nutley, USA)

**Gerard Wagemaker** (Erasmus University Rotterdam, The Netherlands)

**Jesper Wengel** (University of Southern Denmark, Odense, Denmark)

For further information and registration, please visit  
[www.ip-right.org](http://www.ip-right.org)

### RIGHT: RNA Interference Technology as Human Therapeutic Tool

The RIGHT project aims to exploit the vast potential of RNA interference (RNAi) for human therapy. RIGHT involves 22 research institutes and enterprises throughout Europe and is supported by the European Commission's Sixth Framework Programme for Research and Development (FP6). RIGHT combines the strengths of several synergistic competence domains to overcome key technological barriers such as undesired interferon response and insufficient delivery, stability and targeting of RNAi to the appropriate cells. Efficient RNAi reagents are generated both through chemical synthesis of siRNA and vector based gene therapy approaches using shRNA. Strategies are developed for efficient delivery to cells and tissues of diseased organisms. Cell biology and disease models are used to allow addressing their function and effectiveness for the treatment of representative diseases.

This symposium will deepen the insights into potential therapeutic applications and encourage the discussion on novel strategies to diagnose and successfully treat severe unvanquished diseases.

Organising committee: Annick Harel-Bellan, Simone Hess, Elke Müller  
 Symposium secretariat: Katharina Meyer, Sara Skogsäter, Dominique Wasqel

Generously sponsored by

invitrogen



Ambion<sup>®</sup>  
 THE RNA COMPANY<sup>™</sup>  
 An Applied Biosystems Business

BECKMAN  
 COULTER

DHARMACON  
 RNA TECHNOLOGIES